Item type |
琉球大学リポジトリ登録用アイテムタイプ(1) |
公開日 |
2023-07-25 |
タイトル |
|
|
タイトル |
Itch as a critical factor in impaired health-related quality of life in patients with plaque psoriasis achieving clear or almost-clear skin: Analysis of the singlearm, open-label, multicenter, prospective ProLOGUE study |
|
言語 |
en |
作成者 |
Miyagi, Takuya
Kanai, Yasumasa
Murotani, Kenta
Okubo, Yukari
Honma, Masaru
Kobayashi, Satomi
Seishima, Mariko
Mizutani, Yoko
Kitabayashi, Hiroki
Imafuku, Shinichi
|
アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
権利情報 |
|
|
言語 |
en |
|
権利情報 |
© 2022 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. |
権利情報 |
|
|
言語 |
en |
|
権利情報Resource |
https://creativecommons.org/licenses/by/4.0/ |
|
権利情報 |
This is an open access article under the CC BY license |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
absolute PASI |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
brodalumab |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
health-related quality of life |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
itching |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
plaque psoriasis |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
real-life patients |
内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Patients with psoriasis report impaired health-related quality of life (HRQoL; Dermatology Life Quality Index score $ 2) even after achieving clear or almost-clear skin with biologic treatment. Objective: To assess the effectiveness of brodalumab in HRQoL improvement and the factors associated with incomplete HRQoL improvement in Japanese patients with psoriasis. Methods: As a part of the single-arm, open-label, multicenter, prospective ProLOGUE study (Japan Registry of Clinical Trials identifier: jRCTs031180037), patients were treated with 210 mg of subcutaneous brodalumab in daily clinical practice until week 48. The absolute Psoriasis Area and Severity Index scores and patient-reported outcomes were assessed at baseline and weeks 12 and 48. Results: Seventy-three patients (male, 82.2%; median age, 54.0 years) were enrolled. The Dermatology Life Quality Index and European Quality of Life 5-Dimension 5-Level Utility Index scores significantly improved from baseline to weeks 12 and 48. At week 48, all 13 patients with a Dermatology Life Quality Index score of $2 and an absolute Psoriasis Area and Severity Index score of 0 to #2 reported itching. Limitations: Unclear generalizability of the results to other biologics. Conclusion: Treatment with brodalumab improved HRQoL in patients with psoriasis. Itching may contribute to incomplete HRQoL improvement in patients who have achieved clear or almost-clear skin. ( JAAD Int 2022;8:146-53.) |
|
言語 |
en |
出版者 |
|
|
言語 |
en |
|
出版者 |
© 2022 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. |
言語 |
|
|
言語 |
eng |
資源タイプ |
|
|
資源タイプ |
journal article |
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1016/j.jdin.2022.06.013 |
収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2666-3287 |
収録物名 |
|
|
言語 |
en |
|
収録物名 |
JAAD International |
書誌情報 |
巻 8,
p. 146-153,
発行日 2022-09
|